Spectrum Pharma, Viropro in deal for biosimilar rituximab
This article was originally published in Scrip
Executive Summary
The US biotech company Spectrum Pharmaceuticals has signed a binding letter of agreement with Viropro Inc for the development and production of a biosimilar version of Roche/Biogen Idec's monoclonal antibody drug rituximab (Rituxan) ahead of various patent expirations. But financial terms were not revealed.